ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.77 and traded as high as $10.68. ProPhase Labs shares last traded at $10.26, with a volume of 51,993 shares.
Analysts Set New Price Targets
A number of equities research analysts recently commented on PRPH shares. StockNews.com downgraded ProPhase Labs from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 30th. TheStreet downgraded ProPhase Labs from a “b” rating to a “c+” rating in a report on Tuesday, August 23rd. Finally, Dawson James downgraded ProPhase Labs from a “neutral” rating to a “sell” rating in a report on Thursday, July 21st.
ProPhase Labs Price Performance
The company has a quick ratio of 3.93, a current ratio of 4.20 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $164.22 million, a PE ratio of 6.84 and a beta of -0.40. The company has a 50-day moving average of $11.33 and a 200 day moving average of $9.77.
Institutional Trading of ProPhase Labs
About ProPhase Labs
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
- Get a free copy of the StockNews.com research report on ProPhase Labs (PRPH)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.